Reyataz 300 mg Capsule
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Reyataz 300 mg Capsule contains atazanavir, an HIV-1 protease inhibitor. It is used in combination with other HIV (antiretroviral) medicines to treat HIV-1 infection, generally together with low-dose ritonavir. Its labelling describes it for adults and for children aged 6 years and older who weigh at least 15 kg, at the dose and duration set by the prescriber.
Product Information
The following description reflects information associated with atazanavir and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Used in combination with other HIV (antiretroviral) medicines to treat HIV-1 infection
- Described for adults and for children aged 6 years and older who weigh at least 15 kg, generally boosted with low-dose ritonavir, per prescribing information
- Described as lowering the amount of HIV in the body, which is described as helping the immune system work better and reducing the risk of HIV-related complications such as opportunistic infections and certain cancers
Described Dosage & Administration
- Taken by mouth once daily, at about the same time each day, at the dose and duration set by the prescriber
- Capsules are described as needing to be swallowed whole — not crushed or chewed
- Generally co-administered with low-dose ritonavir and taken with food, per prescribing information
- For children, the dose is described as based on body weight and not exceeding the adult dose
- Doses should not be skipped, to maintain effective drug levels
Described Side Effects
Commonly described side effects include:
- Nausea and vomiting
- Headache
- Fever
- Low or depressed mood
- Yellowing of the skin or eyes (raised bilirubin)
These are described as tending to settle on their own. More serious effects — including severe skin reactions, jaundice or liver problems, and raised blood sugar levels — are described as needing prompt medical attention. Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- Atazanavir is described as interacting with a number of other medicines; all current medicines, including antacids, proton-pump inhibitors, other acid-reducing agents, and herbal products such as St John’s Wort, should be disclosed to the prescriber before starting treatment
- Complete medical history, including liver disease (such as hepatitis B or C), diabetes or raised blood sugar, kidney stones, gallbladder problems, haemophilia, or heart-rhythm conditions, should be shared with the prescriber
- Pregnant women and breastfeeding mothers should consult their doctor before starting treatment
- Any persistent or severe side effects should be reviewed by a clinician
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling, it contains atazanavir, an HIV-1 protease inhibitor used in combination with other antiretroviral medicines to treat HIV-1 infection in adults and in children aged 6 years and older who weigh at least 15 kg, generally boosted with ritonavir. SDO Pharma has not independently verified these claims.
Per prescribing information, atazanavir is generally co-administered with low-dose ritonavir and other antiretroviral agents, and taken with food. Antacids and acid-reducing medicines require careful timing or may be contraindicated.
Its labelling describes the capsule as being swallowed whole — not crushed or chewed — once daily at about the same time each day, with food. For children, the dose is described as based on body weight and not exceeding the adult dose. Exact dosing is set by the prescriber.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.